Literature DB >> 22057145

The value of procalcitonin measurements in children with familial Mediterranean fever.

Selçuk Yüksel1, Mesiha Ekim, Z Birsin Ozçakar, Fatoş Yalçınkaya, Banu Acar, Derya Oztuna, Nejat Akar.   

Abstract

It is well known that the serum procalcitonin (PCT) levels increase in severe bacterial infections. However, there is little information about the levels of PCT in diverse diseases except mainly the infectious diseases. The aim of this study was to investigate the progress of serum levels of PCT together with traditional acute phase reactants in children with familial Mediterranean fever (FMF) during the attack and attack-free periods and to test whether PCT could help to diagnose the attack in FMF patients. The study group comprised 21 FMF patients (mean age 10 ± 4.6 years) and 19 healthy controls (mean age 10.6 ± 4.2 years). Serum levels of PCT and traditional acute phase reactants were measured during the attack and attack-free periods. Blood samples were obtained within the first 6-24 h of the attack period, 7 days later, and at least 2 months after the attack. Traditional acute phase reactants (hs-CRP, ESR, and fibrinogen) during the attack period were significantly higher than the attack-free levels and controls. PCT levels of the FMF patients during the attack period were also significantly higher than the attack-free and control group levels (median values, 0.044 ng/ml vs. 0.028 ng/ml and 0.031 ng/ml, P = 0.04, respectively). Although this difference was statistically significant (P = 0.04), median PCT values of the attack, attack-free period, and healthy subjects were lower than 0.05 ng/ml. As a result, these findings suggested that PCT levels were not conspicuously affected from inflammation and could not be used as a descriptive marker for attack in FMF patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057145     DOI: 10.1007/s00296-011-2206-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

Review 2.  Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update.

Authors:  Luciana Breda; Manuela Nozzi; Sara De Sanctis; Francesco Chiarelli
Journal:  Semin Arthritis Rheum       Date:  2009-02-26       Impact factor: 5.532

3.  Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients.

Authors:  G A Wanner; M Keel; U Steckholzer; W Beier; R Stocker; W Ertel
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

4.  Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections.

Authors:  D Gendrel; J Raymond; J Coste; F Moulin; M Lorrot; S Guérin; S Ravilly; H Lefèvre; C Royer; C Lacombe; P Palmer; C Bohuon
Journal:  Pediatr Infect Dis J       Date:  1999-10       Impact factor: 2.129

5.  Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro.

Authors:  M Oberhoffer; I Stonans; S Russwurm; E Stonane; H Vogelsang; U Junker; L Jäger; K Reinhart
Journal:  J Lab Clin Med       Date:  1999-07

6.  CRP levels in autoimmune disease can be specified by measurement of procalcitonin.

Authors:  V Schwenger; J Sis; A Breitbart; K Andrassy
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

7.  The use of procalcitonin determinations in evaluation of systemic lupus erythematosus.

Authors:  Gerardo Quintana; Yimy F Medina; Cilia Rojas; Andrés Fernandez; José Félix Restrepo; Federico Rondon; Antonio Iglesias
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

8.  The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial mediterranean fever.

Authors:  Bulent Colak; Bahar Gurlek; Zeynep Arzu Yegin; Serpil Muge Deger; Sehri Elbek; Hatice Pasaoglu; Ibrahim Dogan; Mehmet Akif Ozturk; Selahattin Unal; Galip Guz
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

9.  Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?

Authors:  I Delèvaux; M André; M Colombier; E Albuisson; F Meylheuc; R-J Bègue; J-C Piette; O Aumaître
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

10.  Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?

Authors:  Bunyamin Kisacik; Umut Kalyoncu; M Fatih Erol; Omer Karadag; Mustafa Yildiz; Ali Akdogan; Bugra Kaptanoglu; Mutlu Hayran; Kemal Ureten; Ihsan Ertenli; Sedat Kiraz; Meral Calguneri
Journal:  Clin Rheumatol       Date:  2007-04-06       Impact factor: 2.980

View more
  3 in total

1.  Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.

Authors:  Mustafa Çakan; Nuray Aktay Ayaz; Gonca Keskindemirci; Şerife Gül Karadağ; Ayşe Tanatar; Hafize Emine Sönmez
Journal:  Clin Rheumatol       Date:  2019-09-04       Impact factor: 2.980

2.  Diagnostic Value of Procalcitonin in ANCA-Associated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity.

Authors:  K Herrmann; S Schinke; E Csernok; F Moosig; J U Holle
Journal:  Open Rheumatol J       Date:  2015-10-09

Review 3.  Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome.

Authors:  Per Wekell; Anna Karlsson; Stefan Berg; Anders Fasth
Journal:  Acta Paediatr       Date:  2016-08-19       Impact factor: 2.299

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.